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Abstract 
Obesity is an ongoing global health concern and has only recently been recognized as a 
chronic disease of energy homeostasis and fuel partitioning. Obesity afflicts 17% of US 
children and adolescents. Severe obesity (120% of the 95th percentile of BMI-for-age, 
or a BMI of 35 kg/m2) is the fastest growing subgroup and now approaches 6% of all 
US youth. Health consequences (e.g., type 2 diabetes, coronary heart disease) are 
related in a dose-dependent manner to severity of obesity. Since therapeutic 
interventions are less effective in severe obesity, prevention is a high priority.  
Treatment plans involving combinations of behavioral therapy, nutrition and exercise 
achieve limited success. Only one drug, orlistat, is FDA-approved for long-term obesity 
management in adolescents 12 years and older. As part of comprehensive medication 
management, clinicians should consider the propensity for a given drug to aggravate 
weight gain and to consider alternatives that minimize weight impact. Medication 
management must take into account developmental changes as well as 
pathophysiology of obesity and comorbidities.  
Despite expanding insight into obesity pathophysiology, there are gaps in its translation 
to therapeutic application. The historical construct of obesity as simply a fat storage 
disorder is fundamentally inaccurate.   
The approach to adjusting doses based solely on body size and extrapolating from 
therapeutic knowledge of adult obesity may be based on assumptions that are not fully 
substantiated. Classes of drugs commonly prescribed for comorbidities associated with 
obesity should be prioritized for clinical research evaluations aimed at optimizing dosing 
regimens in pediatric obesity.  
 
 
  
Keywords Adolescent medicine, Obesity, Pediatrics, Type 2 diabetes, Therapeutics, 
Comprehensive medication management 
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Introduction  
Pediatric obesity with its metabolic complications is a public health problem recognized 
as a major contributor to health burden on a global scale. Clinical data supports the 
American Medical Association’s decision in 2013 to designate obesity as a disease.1 
The obesity epidemic has led to the emergence among adolescents of what have 
previously been predominantly adult-onset diseases: type 2 diabetes, hypertension, 
nonalcoholic liver disease, dyslipidemia and obstructive sleep apnea.2 Direct medical 
costs for provision of care to obese patients in the United States was estimated at $147 
billion per year in 2008.3 Such estimates of incremental cost of care do not include 
diminished quality of life for patients and their families, which is part of the cost of 
obesity with its attendant morbidities.  
 
Considering that cases are projected to increase over time, the future costs to society 
are staggering.  Many factors must be considered in planning how best to apportion 
health care resources, how to determine clinical priorities and treatment approaches, 
how to prioritize clinical research, and how to advance drug development for more and 
better treatment options. 
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Definitions of Obesity in Children and Adolescents  
 
While it is an imperfect measure of body fat, body mass index (BMI) correlates fairly 
well with percentile rankings of percent body fat when it is measured by more direct 
methods.4 BMI is the most commonly used clinical screening measure of overweight 
and obesity, followed by waist circumference and waist-to-hip ratio as clinical measures 
of intra-abdominal adipose tissue accumulation, called visceral adiposity. In extremely 
obese youth, waist circumference is not recommended because it is less accurate in 
this subgroup.4 
 
BMI growth charts are tools for tracking changes in overweight and obesity status 
among children aged ≥2 years. Since a child grows in weight as well as height, the 
norms for BMI (the quotient of weight in kilograms and the square of height in meters, 
expressed as kg/m2) vary with age and sex, as seen in the charts and online calculator 
from the Centers for Disease Control and Prevention (CDC).5,6 
 
Children aged ≥2 years are diagnosed as obese if the BMI is ≥95th percentile for age- 
and sex-based on the CDC growth charts published in May 2000, which is the most 
current. A diagnosis of overweight is made if BMI is ≥85th percentile but <95th percentile 
for age and sex.7 For a child <2 years, obesity is diagnosed when the weight for 
recumbent length is ≥97.7th percentile of the growth standards of the World Health 
Organization (WHO).8 
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Severe obesity, also known as extreme obesity, is defined as either a BMI-for-age 
≥120% of the 95th percentile or a BMI of 35 kg/m2. These criteria correspond to the 99th 
percentile. Some clinician-researchers further stratify this subgroup of adolescents and 
young adults with high BMI to better predict risk for developing metabolic abnormalities, 
i.e., insulin resistance (IR) and altered glucose metabolism, low high-density lipoprotein 
(HDL) cholesterol and high systolic blood pressure.4 Using this approach, severe 
obesity is categorized as class 2 obesity, while class 3 is a BMI-for-age ≥140% of the 
95th percentile or a BMI of 40 kg/m2.  
 
This upward shift in BMI is a concern for the health of populations both now and far into 
the future.9 Higher levels of obesity carry the greatest cardiometabolic risk and potential 
for serious disease, complications and disability into adulthood. Furthermore, responses 
to treatment approaches are less effective in severe obesity.10  
 
Prevalence and Epidemiology  
 
As of 2014, obesity afflicts 17.2% of all US children and adolescents, aged 2 to 19 years 
old, and another 16.2% are overweight.11 Taken together, overweight and obese 
individuals encompass about one-third of youth in the United States,12 as well as in the 
United Kingdom.13 
 
US statistics on trends in childhood obesity utilize measured height and weight data 
obtained by the National Health and Nutrition Examination Survey (NHANES) over 
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many decades.  Based on data collected through 2013-2014, the most recent update, 
obesity either slowed its pace of rise or plateaued in certain age subgroups (Figure 1), 
but the durability of this trend remains to be seen.  
 
As shown in Figure 2, there are racial/ethnic differences and sex differences in obesity 
occurrence in the US pediatric population. Notable are the low occurrence among Asian 
girls and the relatively high prevalence among Hispanics and Mexican Americans of 
both sexes. 
 
More than half of the world’s obese youth reside in countries with low- to middle-income 
economies. Statistics from these countries are sparse and may not be directly 
comparable to those generated in the United States if they use the child growth 
standards of the World Health Organization or national standards, rather than those of 
the CDC. In 2012, 37% of school-aged boys in Mexico were overweight or obese.14 
Latin American countries face a dual challenge of pediatric obesity and undernutrition. 
Through improved nutrition and daily physical activity programs at school, the Pan 
American Health Organization emphasizes prevention and weight management.14 
 
With a continuously upward trend in its prevalence, severe obesity is the fastest growing 
subgroup.4 In NHANES data collected from 2011 to 2014, severe obesity afflicted 5.8% 
of US youth overall.12 Among ethnic/racial subgroups, severe obesity was highest 
among non-Hispanic blacks at 8.6%, followed by Hispanics at 7.6%. For other non-
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Hispanic pediatric groups, the prevalence was 4.4% among white youth, and lowest 
among Asians at 1.3%.12 
 
It is important to note that the correct interpretation of BMI among ethnic minorities is 
based upon ethnic norms. There are pediatric racial/ethnic differences in the percentage 
of body fat at a given BMI. With their body composition and pattern of lipid partitioning, 
Asians begin to develop cardiovascular risk at lower BMI thresholds.7,15 Using standard 
BMI cut points likely underestimates health risk among pediatric Asians.  
 
As another means of describing unhealthy body composition, there are individuals with 
excess body fat even though their BMI might be normal, i.e., not overweight or obese. 
As was reported in one world region examined in 2008 in the CASPIAN study, this body 
composition described as many as 25% of adults.16,7 
 
A recent public health report defined an overfat phenotype as excess body fat that can 
impair health, at any BMI. The umbrella term overfat encompasses not only overweight 
and obese but also “metabolically obese, normal weight” (MONW) such as visceral 
obesity. It affects about half of children residing in 30 developed countries17 and as 
many as 69% of youth (2 to 19 years) in the United States.18 
 
Because excess body fat is associated with increased cardiometabolic risk,18 MONW 
might be a factor contributing to heterogeneity among normal body weight patients 
recruited into metabolic research studies or in patient care settings, particularly among 
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ethnic populations known to have low BMI values.19 Again, it is important to note the 
limitations of interpreting BMI similarly across all ethnic groups.   
 
While there is no standardized definition, the obesity phenotype described as 
“metabolically healthy obesity” (MHO) is described as obesity with high insulin 
sensitivity and without diabetes, dyslipidemia or hypertension. MHO prevalence, which 
varies with the criteria applied,20 ranges from 20 to 30% of obese individuals of any 
age.21 Importantly, MHO may represent a step toward metabolically unhealthy 
obesity,22,23 at which point there is evidence of biochemical and metabolic changes. 
Whether drug disposition might be different in metabolically healthy obesity, as an early 
stage of the disease in youth or adults, compared to later stages of obesity is worth 
conjecture and scientific inquiry.  
 
Obesity Pathogenesis  
 
Obesity was once regarded simply as a storage disorder of adipose tissue. It is now 
described as a complex disorder of energy balance that involves adipocytes, the 
gastrointestinal tract, and the brain, through its operational control of food intake and 
energy expenditure. With ample evidence that the disorder has many features of a 
chronic systemic disease,1 there is much ongoing research into the gut-brain axis, 
neurobiology determinants of body fat mass, as well as the interplay of genetics, 
epigenetics, developmental influences and the environment. There rarely is a single 
genetic cause of an underlying hormonal abnormality that leads to early weight gain in 
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infants. A discussion of these topics is beyond the scope of this paper, but can be found 
in a recent review.24 What follows is a brief overview of pathophysiology of obesity to 
support an understanding of pharmacotherapy. 
 
In overweight or obese individuals, there is a sustained positive energy balance (energy 
intake exceeding energy expenditure) combined with an inherited predisposition for 
weight gain. A related but distinct process is that body weight is maintained at a stable 
range, referred to as the set point, regardless of variation in energy intake and 
expenditure. The control mechanism is located in the lateral hypothalamus. The body 
has evolved to be efficient at protecting against weight loss during food deprivation or 
low intake. Weight that is gained is biologically defended, through biologic mechanisms 
that are still being elucidated. The higher weight then reestablishes the individual’s set 
point at an elevated value.  
 
Bariatric surgery, e.g., Roux-en-Y gastric bypass (RYGB), appears to lower the set 
point, accompanied by weight loss and high rates of remission of type 2 diabetes.25 
Surgery has potential side effects, however, and is not a feasible option for many 
adolescents since it is only considered in mature teenagers who have access to skilled 
surgical centers and insurance coverage. These facts should reinforce the importance 
of slowing the rate of weight gain or avoiding weight gain during adolescence by lifestyle 
interventions, i.e., physical activity and nutritional meal planning, along with 
pharmacotherapy.  
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Several key organs and peptide hormones are involved in human energy 
homeostasis.26 The peptide ghrelin is orexigenic, as it signals from the stomach to the 
brain to stimulate appetite. Insulin, on the other hand, signals the brain to curtail 
feeding. This is in addition to insulin’s actions that promote nutrient uptake into muscle, 
liver and fat.  
 
In addition to fatty acids, adipose tissue is an endocrine organ that produces 
hormones.27 The adipocyte hormone leptin circulates in concentrations that are 
proportional to body fat mass.28 It is believed that leptin evolved to be a metabolic 
switch that controls fat retention during periods of famine.27 Intact leptin-regulated 
neuronal circuitry is required for body weight and energy homeostasis. During and 
following loss of weight, there is a decline in leptin blood concentrations, which alters 
the brain’s executive function and reward aspects of eating behavior. As a 
consequence, there is both a stimulation of feeding and a reduction in energy 
expenditure. Together these processes defend a higher level of body fat and serve to 
restore body weight to its original set point.24 This physiologic response to weight loss 
likely explains the regain of weight following initial successful weight loss from most 
forms of obesity treatment.  
 
It seems particularly advantageous to avoid large weight gains prior to the time when 
the set point is established, since the highest body weight will be physiologically 
defended. It is unclear, however, when the set point is fixed but it is thought to happen 
sometime before adulthood, i.e., later adolescence.29 Knowing this timing might help 
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clinicians determine when to initiate pharmacotherapy for weight loss/management and 
to intensify efforts to achieve individualized body weight goals.  
 
Leptin has a direct influence on lipid partitioning into skeletal muscle and adipocytes. It 
is hypothesized that the relative proportion of lipids in fat deposits, rather than the 
absolute amount, is the main determinant of metabolic risk. Different patterns of lipid 
partitioning may explain why some obese individuals develop comorbidities and others 
do not.24 
 
Currently no pharmacologic therapy is known to lower the weight set point. Although 
recombinant human leptin analog, a marketed product for leptin deficiency and 
generalized lipodystrophy, is contraindicated in general obesity, it was experimentally 
shown to prevent the regain of weight in previously obese individuals who lost 
weight.30,31 This finding adds credence to the theory that a pharmacologic agent could 
be developed to reset the defended body weight in obese people to a value that is 
closer to normal.32,24 
 
Other molecules (i.e., gut peptides, neurotransmitters, cytokines, steroid hormones, 
enzymes) play a role in human energy homeostasis.27 As underlying mechanisms are 
elucidated, it is expected to have a positive impact on developing new therapies to 
regulate body weight. 
 
 12
Clinical Aspects: Comorbid Conditions  
  
Obesity is accompanied by significant health problems. Most obese children continue to 
be obese as adults. Even early in childhood, weight-related morbidities can emerge. 
Childhood obesity is a risk factor for hypertension, type 2 diabetes, metabolic syndrome, 
and liver disease during adolescence, as well as for premature death in adulthood.  
 
Pediatric clinical practice guidelines advise that children or adolescents with a BMI  
85th percentile be clinically evaluated for potential comorbidities, especially altered 
glucose metabolism with whole-body reduced insulin sensitivity, and fatty infiltration of 
the liver, known as nonalcoholic fatty liver disease (NAFLD).7 These conditions are 
among the first obesity-related comorbidities to emerge in childhood. Clinical 
manifestations of cardiometabolic risk and atherogenesis might develop sooner in boys 
than in girls, in whom high post-pubertal estrogen levels lower cardiovascular risk.10 
 
The clustering of cardiometabolic risk factors, referred to as metabolic syndrome, is 
associated with increased BMI across different ethnic and racial groups of severely 
obese youth. Severe obesity is accompanied by a marked elevation of leptin that 
indicates abnormal satiety signaling and signifies future weight gain over time.4  
 
When severe obesity has its onset during childhood, it portends a high level of 
cardiovascular and metabolic risk and a high prevalence of type 2 diabetes. Since 
severe obesity was uncommon decades ago, longitudinal data on health outcomes are 
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still accruing. It is too soon to know the extent to which health outcomes will be more 
grave and costly in severely obese youth (class 2 or 3, see Definitions of Obesity) 
compared to children with normal body weight or even to those with class 1 obesity.  
 
In addition to cardiovascular disease and diabetes, obesity is associated with numerous 
other conditions or risk factors (Table 1).15 Prominent among these are hepatic and 
gastrointestinal diseases.33  
 
Obesity is considered a direct cause of NAFLD.34 Associated with both visceral 
adiposity and insulin resistance, NAFLD is the most common type of pediatric liver 
disease.2 NAFLD is a spectrum of liver disease that necessitates attention to dosage 
adjustments as may be appropriate for certain hepatically-cleared drugs.35 In its most 
severe form, NAFLD can lead to cirrhosis and even liver transplant in adolescents.  
 
Obesity is a risk factor for reflux esophagitis and gallstones. These gastrointestinal 
disorders might present at an earlier age or as a more complicated disease than in the 
absence of excess weight. 
 
Additional conditions associated with obesity include obstructive sleep apnea, 
depression and other psychiatric conditions and disordered eating (i.e., binge eating 
and loss-of-control eating).36 Negative effects of weight gain include an increased 
cancer risk with some cancers having an onset in early adulthood.37 It is not well-
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appreciated by the public that excess body fat leads to greater risk for at least 13 
different types of invasive cancers (e.g., colon, kidney, thyroid and pancreas).38  
 
Most obesity-associated health conditions are chronic diseases that eventually require 
drug treatment. More studies are needed in the pediatric population to safely and 
effectively manage these common comorbidities with pharmacotherapy.  
 
Clinical Aspects of Medication Use: Medications Affecting Body Weight  
 
Introduction 
Some drugs are associated with an undesired gain in body weight (Table 2), which can 
aggravate the underlying medical condition being managed with pharmacotherapy and 
lead to medication nonadherence.39 If the agent is taken on an ongoing basis, weight 
gain is cumulative.  
 
A medication management review of obese pediatric patients can help identify current 
or planned medications with a propensity to exacerbate weight gain. This section 
highlights several therapeutic classes of interest to this population, along with some 
alternative drugs with no known obesogenic effects in youth. It should be noted that 
some alternative drugs might be prescribed in youth despite being off-label for pediatric 
use based on current FDA-approved prescribing information.40 
 
Glucocorticoids  
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With 60 years of clinical use, it is widely known that glucocorticoids impact body weight 
and fat distribution. Glucocorticoids stimulate appetite, despite elevations in leptin, and 
influence food preference towards protein and carbohydrates which lead to increased 
energy intake in excess of energy expenditure.41 Glucocorticoid-induced weight gain 
and lipodystrophy also involve effects on central and peripheral adipose tissue.42 Since 
glucocorticoid receptor density is higher in visceral adipose tissue relative to other fat 
depots, glucocorticoid-induced weight gain is typified by central (visceral) fat 
accumulation but with possible thinning of subcutaneous fat. This pattern of 
lipodystrophy is related to glucocorticoid effects on peripheral fat, where lipolysis is 
increased and lipoprotein lipase activity is decreased.42 The net effect is adipose tissue 
expansion as well as fat redistribution. 
Weight gain is most notable at prednisone daily doses of 5 mg.43 The lowest possible 
dose is advisable in pediatric patients to minimize negative effects on linear growth and 
development as well as body weight.44 Depending on the indication, the substitution or 
addition of another effective, non-steroidal drug may provide a steroid-sparing effect. 
 
Diabetes Medications  
 
Several anti-diabetes drugs cause weight gain, which intensifies cardiovascular risk 
factors accompanying diabetes. Insulin is associated with weight gain, although the 
magnitude of effect varies with the intensity of the overall diabetes treatment regimen 
and with the type of insulin.  
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In two randomized trials in pediatric patients with type 1 diabetes, insulin detemir had a 
more favorable effect on body weight than NPH insulin.45,46 BMI was standardized (i.e., 
corrected for growth) to compare across the age range of 347 youth (6 to 17 years) in 
one six-month study45 as well as in 347 children (2 to 16 years) in a one-year trial.46 At 
the end of both trials, weight46 or standard deviation weight scores45 were increased 
with NPH insulin but slightly decreased with insulin detemir.  
 
Adult data support this finding for insulin detemir relative to NPH and basal insulin 
analogs at similar levels of glycemic control and hypoglycemia risk. In overweight adults 
with type 1 diabetes, NPH insulin was associated with a weight gain of 1.72.46 kg, 
whereas insulin detemir exhibited slight weight reduction (0.71.85 kg) after 16 weeks.47 
The physiological basis of this intrinsic property of insulin detemir is primarily reduced 
caloric intake (unrelated to hypoglycemia frequency), with the brain playing a key role in 
mediating the reduction of energy intake.47,48  
 
The differing effects among insulin analogs provide caution against judging drug-
associated weight gain as a pharmacologic effect common to all drugs in a given class. 
Each drug should be considered individually and monitored for body weight change 
during chronic dosing. 
 
In pediatric diabetes management, it is common to initiate metformin. Metformin is less 
effective in youth-onset compared to adult-onset type 2 diabetes.49 Nearly half of youth 
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with new-onset type 2 diabetes do not maintain adequate glycemic control with 
metformin monotherapy, with a median time to failure of about 11 months.50 
 
Combinations of drugs acting by different mechanisms and including one or more 
weight-sparing or weight-losing drugs may be tried. This approach may allow a lower 
dosage of the diabetes drugs contributing to weight gain, which in pediatric patients 
might be a sulfonylurea (e.g., glimepiride, glyburide, glipizide), injectable insulin, and 
possibly a thiazolidinedione (e.g., rosiglitazone), which was studied in the TODAY trial.39 
Newer anti-diabetes agents with favorable effects on body weight include glucagon-like 
peptide-1 (GLP-1) receptor agonists, such as liraglutide and lixisenatide pen injector 
devices.51  
 
Ongoing pediatric trials using adult anti-diabetes pharmacotherapy may lead to more 
choices and perhaps a labeled indication for treating diabetes without aggravating 
weight control. More and better options are particularly needed among young patients 
with diabetes and severe obesity. 
 
Antipsychotics, Second Generation  
 
Antipsychotic (AP) drugs are effective across a wide span of pediatric ages for the 
indications of autism spectrum disorder, schizophrenia, bipolar disorder, aggression and 
tics.52 
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With the advent of atypical or second-generation antipsychotics (SGAs), e.g., 
risperidone, olanzapine, quetiapine, introduced in the late 1990s, APs were heralded for 
less motor effects than traditional neuroleptics. That favorable safety feature was offset, 
however, by enduring negative effects on body weight, insulin resistance and lipid 
levels.53 
 
The long-term impact of SGAs on weight along with metabolic and cardiovascular 
consequences, when instituted early in life, is now being realized as a generation of 
youth with psychiatric illness has been exposed to them for about two decades.54 
 
Weight gain is evident soon after initiating antipsychotic therapy. Among 272 treatment-
naïve youth (from 4 to 19 years) initiated on SGAs, substantial weight gain was evident 
during the first 3 months of treatment.55 Weight gain was highest with olanzapine (mean 
+8.5 kg, 95% CI 4.9 to 7.2) and lowest with aripiprazole (mean +4.4 kg, 95% CI 3.7 to 
5.2), with quetiapine- and risperidone-treated youth showing intermediate effects (mean 
+6.1 kg and +5.3 kg, respectively).  
 
Furthermore, over half of the patients55 experienced a clinically important change in 
body weight, defined as >7% increase compared to baseline within 3 months of starting 
SGA monotherapy.56 An individual’s vulnerability to significant weight gain is likely a 
combination of genetics, neurotransmitters, hormones, neuropeptides and lifestyle 
behaviors.R After accounting for weight gain expected in growing youth, the magnitude 
of weight gain with SGAs is greater in children and adolescents compared to adults.57,56 
 19
 
Adding metformin may slow the rate of weight gain or even decrease body weight 
during maintenance treatment. In a multi-center study of 61 autism spectrum disorder 
patients who experienced >7% increase in body weight during treatment with SGAs, 29 
youth were randomized to metformin liquid formulation, either 500 twice daily (for ages 
6 to 9 years) or 850 mg twice daily (10 to 17 years), and 32 to placebo.58 The primary 
study endpoint, the BMI standard deviation score (BMI z score), showed statistically 
greater reduction from baseline to week 16 among metformin-treated patients (-0.10, 
95% CI, -0.16 - -0.04, p=0.003).58 There were no significant effects on lipids, fasting 
insulin, fasting glucose, hemoglobin A1c (HbA1c) or other indicators of negative 
cardiometabolic consequences of SGA medication. It is speculated that the later 
findings were biochemical evidence of the cardiometabolic benefit of metformin 
offsetting SGA effects.58 Gastrointestinal side effects were common but well-tolerated, 
and not a reason for study discontinuation by 5 children in the metformin group.  
 
Other SGAs with FDA-approved pediatric indications produce weight gain of varying 
degrees compared to placebo, as reported in their product label: asenapine,59 
lurasidone,60 and paliperidone.61 Comparative trials with active control treatment arms 
are needed to understand the relative magnitude of weight gain with these newer SGAs. 
 
Antidepressants 
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Antidepressants are increasingly prescribed for pediatric depression, anxiety disorders 
and obsessive-compulsive disorder. The selective serotonin reuptake inhibitors (SSRIs) 
citalopram and escitalopram were strongly associated with increase in BMI, visceral fat 
mass and visceral fat mass index in 264 older adolescents, aged15 to 20 years, who 
had not been medically treated within one month of initiating the antidepressant. The 
association with body composition was weaker for fluoxetine, whereas sertraline was no 
different than no SSRI treatment.62 Psychological therapy is an option that could be 
considered since it can achieve similar response rates as medication in children and 
adolescents with depression.63 
 
Antiepileptic Drugs  
 
Antiepileptic drugs have variable effects on body weight, based on reports from mixed 
age groups and not specifically pediatric populations.39 Sodium valproate (i.e., valproic 
acid), gabapentin, pregabalin and vigabatrin cause weight gain.64 Phenytoin, lamotrigine 
and levetiracetam are weight-neutral, whereas felbamate, topiramate and zonisamide 
can result in weight loss.64,65 
 
Clinical Aspects: Interventions For Control of Body Weight  
 
Introduction 
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Lifestyle interventions ideally are family-based efforts towards improving the patient’s 
diet and lowering its caloric intake. These efforts are combined with increased physical 
activity and reduced sedentary behaviors. These lifestyle interventions are the 
foundation upon which drug treatment and surgery may be added. Bariatric surgery 
shows substantial improvement in weight loss and obesity-associated comorbidities. 
More knowledge is needed about the efficacy, safety and long-term consequences of 
bariatric surgery as well as long-term anti-obesity medication in a pediatric population. 
  
Table 3 lists prescription drugs that have been and/or are currently in use in the United 
States for weight loss/management. This section highlights 3 classes of drugs – orlistat, 
metformin, and GLP-1 agonists - with existing or evolving long-term data on weight 
management effectiveness and safety in pediatrics. The mechanisms of action are 
mentioned under each class of medication. 
 
Some of these drugs have been evaluated for beneficial impact on obesity-associated 
comorbidities. In multiyear-long studies in adults, the addition to lifestyle changes of 
either orlistat (Xenical in the Prevention of Diabetes in Obese Subjects, or XENDOS, a 
4-year prospective study)66 or metformin (Diabetes Prevention Program Outcomes 
Study, or DPPOS, a 15-year extension of the landmark DPP trial)67 resulted in a delay 
in onset of type 2 diabetes in adults with prediabetes. Of the two agents, metformin has 
the stronger evidence base for effectiveness and safety for diabetes prevention.67 In 
obese adolescents with IGT and a family history positive for type 2 diabetes, metformin 
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improved glucose homeostasis and may prevent type 2 diabetes.68 There are no data 
on orlistat for diabetes prevention in the pediatric population.4 
 
Orlistat  
 
Currently orlistat is the only medication for long-term pediatric weight management 
approved, in December 2003, by US regulatory authorities. Orlistat is available both as 
a prescription (for children 12 and adults) and a lower strength non-prescription 
product (for 18 years).  
 
In a clinical trial, 539 obese adolescents (with average BMI at the 98th percentile) were 
randomized 2:1 to orlistat or placebo. The primary study endpoint of placebo-subtracted 
BMI change was -0.86 kg/m2 after one year of treatment, representing a BMI reduction 
of 2.4%.69 Both active treatment and placebo groups had dietary instruction for caloric 
reduction accompanied by counseling for diet and exercise. A loss of at least 5% or 
10% of body weight was achieved by 26.5% and 13.3%, respectively, of the orlistat 
group and 15.7% and 4.5%, respectively of the control group. The control group, 
however, did not maintain weight loss beyond 3 months. A 5% to 10% weight reduction 
is generally considered to produce beneficial effects on obesity-associated 
comorbidities, with improvement in their laboratory parameters. 
 
To correct for poor absorption of certain dietary nutrients during orlistat, daily dietary 
supplementations that include fat-soluble vitamins are recommended several hours 
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apart from orlistat, which is dosed with meals, three times a day.7 In a drug interaction 
study in normal weight young adults, orlistat did not significantly alter oral absorption of 
highly fat-soluble drugs fluoxetine or simvastatin that treat depression and dyslipidemia, 
respectively, which are not uncommon comorbidities in adolescent obesity (Table 1).70  
 
Orlistat’s gastrointestinal side effects, while not a significant issue reported in this 
research study, are common and poorly tolerated events related to orlistat’s mechanism 
of action as a gastrointestinal lipase inhibitor and contribute to poor adherence. An 
analysis of orlistat prescription data in children and adolescents in the UK indicate a rate 
of discontinuation, for any reason, of 45% by the end of the first month and 75% by the 
third month.71  
 
Metformin 
 
Metformin has been used for many years for managing pediatric patients with 
overweight or obese individuals.4 Although its use for weight management is off-label, 
metformin is typically prescribed in youth for an on-label concurrent condition, which 
include polycystic ovary syndrome (PCOS), diabetes and prediabetes. A diagnosis of 
prediabetes is suspected when a HbA1c value 5.7% is confirmed by impaired fasting 
plasma glucose (FPG: 100 to 125 mg/dL) or an impaired glucose tolerance (IGT) (2-
hour plasma glucose: 140 to 199 mg/dL).7 Since IGT exists in 10 to 30% of obese 
children and adolescents,15 many of these obese pediatric patients are eligible for 
metformin treatment for a labeled indication. 
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Among 3 randomized controlled trials in which change in weight or BMI was the primary 
endpoint in obese youth 6 to 18 years old, metformin had a modest BMI effect. In these 
studies of 6-months72,73 or one-year duration,74 the placebo-subtracted change in BMI 
averaged -1.1 kg/m2 or approximately 3% reduction of BMI.  
 
Differing responses to metformin as a weight-reducing medication may have multiple 
causes. Metformin tablets display low and variable absorption that could lead to variable 
drug effect. At physiologic pH, metformin is a mono-protonated cation that relies upon 
active transport to cross lipid membranes, including those in the intestine, liver and 
kidney. Hepatic uptake is essential for metformin’s full pharmacologic effect of inhibition 
of hepatic gluconeogenesis and increased insulin sensitivity. At the molecular level in 
the liver, metformin has an effect on the respiratory chain in the mitochondria.75 
Metformin enters the liver, one of its sites of action, by several transporters, the 
predominant being the organic cation transporter 1 (OCT1), which exhibits 
polymorphisms.76 
 
Genome-wide association studies indicate a genetic contribution to metformin’s 
pharmacologic effects. Metformin disposition, pharmacodynamics and 
pharmacogenetics were retrospectively explored in 28 severely obese children.77 
Polymorphisms in the gene SLC22A1 that expresses OCT1 resulted in lower levels of 
this protein transporter. A genetic variant might have negatively impacted metformin’s 
efficacy of reducing adiposity in the subset of obese children who had insulin 
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resistance.77 This hypothesis-generating retrospective analysis should be evaluated in a 
larger prospective comparative trial of obese and non-obese youth. A 
pharmacogenomic approach might optimize dosing regimens and determine which drug 
transporter gene variants predict the patients who are unlikely to achieve clinically 
significant fat reduction or are likely to experience severe gastrointestinal side effects 
during metformin therapy. Furthermore, additional genetic studies of metformin might 
elucidate previously unidentified targets of its multiple molecular mechanisms. 
 
GLP-1 Agonists 
 
Exenatide was the first GLP-1 agonist to receive FDA approval, in 2005, for glycemic 
control in adults with type 2 diabetes. Although weight management is still not a labeled 
indication for any age group, this short-acting incretin mimetic produces weight loss in 
diabetic individuals, mainly or partly by decreasing appetite and slowing gastric 
emptying. In a pooled analysis of data from 32 adolescents 8 to 19 years of age with 
severe obesity enrolled in two small randomized trials, after 3 months of twice daily 
exenatide, the treatment effect on BMI relative to placebo was -3.42% (95% CI: -5.41%, 
-1.42%).78 Predictors of this treatment effect were self-reported appetite at baseline and 
being female. Although not a predictor of response in the analysis, adherence with twice 
daily injections using a pen delivery device presents a challenge for this age group.  
 
Liraglutide is the first GLP-1 mimetic to receive FDA approval, in 2014, for weight 
management with the indication restricted to adults. Liraglutide’s weight loss efficacy 
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and long-term safety at a once daily dose of 3 mg are well-established in adults who are 
either overweight with comorbidities or are obese.79 
  
Liraglutide doses up to 1.8 mg have been studied for safety, pharmacokinetics (PK) and 
pharmacodynamics (PD) in a short-term trial of children and adolescents with type 2 
diabetes but not obesity. Also, data from the obese pediatric population are accruing. 
These data include pharmacokinetic and safety findings from a recently completed trial 
in obese children aged 7 to 11 years, (NCT02696148) and a published safety, 
tolerability and PK study of 5-weeks duration, with dose escalation up to a maximum of 
3 mg in adolescents 12 years (NCT01789086).80 
 
Compared to oral metformin, high dose liraglutide in adults is associated with greater 
weight reduction, but GLP-1 mimetic injections are costly, less convenient and carry risk 
for serious but rare acute pancreatitis and acute gallbladder disease. With supporting 
clinical experience, GLP-1 agonist therapy may eventually become a welcomed 
pharmacologic option for weight control in youth with obesity. 
 
Other Agents: Topiramate and Phentermine  
 
The combination product topiramate/phentermine is indicated for obesity in adults but 
not children. Topiramate has not been studied in long-term randomized controlled trials 
in obese youth. Used in children as young as 2 years as an FDA-approved seizure 
medication, topiramate’s observed anorexigenic and weight loss effects are attributed to 
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the control of cravings.81 Concerning side effects limiting its usefulness in childhood 
obesity include paresthesias, cognitive disruption (confusion, difficulty concentrating) 
and teratogenicity (cleft palate). 
 
Phentermine as a single agent is FDA-approved only in adolescents >16 years for 
short-term weight control (<3 months at a time). This limited exposure achieves small to 
moderate weight loss. As a norepinephrine- and dopamine-releasing agent, 
phentermine may cause anxiety, tremors and slight increases in blood pressure.  
 
Non-Obesity Drugs Used in Hospitalized Pediatric Patients 
 
Table 4 lists commonly used medications in hospitalized pediatric patients and specifies 
whether the medicines have been specifically studied, prospectively or retrospectively, 
in obese individuals. The medication list is based on usage, which was collected in a 
drug interaction database accumulated from 42 U.S. pediatric intensive care units 
(PICUs) for patients ranging from infants, excluding neonates, to 17 years.82  
 
Due to the paucity of published data on children and adolescents, the search for the 
listed drugs was also applied to studies in obese adults. The literature search was 
based on PubMed/Medline database searches October 11-22, 2017, with a publication 
date limit from 1950 to present and English language limit, using the following search 
terms and cross-references: “children” OR “child” or “adolescent” OR “adolescence” OR 
“youth” (included when searching for studies done in those <18 years old) AND “weight 
change” OR “weight gain” OR “overweight” OR “obesity” OR “obese” OR “BMI” OR 
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“Body Mass Index” AND “drug dosing” OR “pharmacokinetics” AND “drug class” OR 
“specific drug name(s).” The search was augmented with a manual review of reference 
lists. 
 
This exploratory literature evaluation focused on 7 therapeutic drug categories, 
excluding drugs that are mainly used in an acute care setting or in the context of 
surgical operations, e.g., propofol, and the neuromuscular blocking agents, rocuronium 
and vecuronium, but including antibiotics. Due to the pressing need to optimize drug 
dosing during, before and after bariatric surgery in recent years, drug research 
evaluations in the context of bariatric surgery have been conducted. A recent literature 
review discussed the following drugs relevant to obese adolescent surgical patients: 
acetaminophen, fentanyl and newer analogs, midazolam, enoxaparin, morphine, 
ketamine and dexmedetomidine.83  
 
The most-used drugs from the PICU study are displayed as a list, ranked in order of 
prevalence of exposure, in Supplemental Table S1. More than half of the hospitalized 
pediatric patients had a prescription dispensed for acetaminophen, the single-most 
frequently ordered drug, with the following exposure rates by age category: infants: 
57.9%, children 1 through 9 years old: 58.0%, adolescents 10 through 17 years old: 
50.7%.82 Despite the high prevalence of exposure to acetaminophen, it has been the 
subject of very few obesity studies in adults84,85 or in children with the obesity-
associated comorbidity of NAFLD.35 In the latter group, there is a concern that the 
cytochrome P450 2E1 pathway might be up-regulated in obesity,86 with the theoretical 
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risk for increased formation of the hepatotoxic acetaminophen metabolite N-acetyl-p-
benzoquinone imine. Until research is conducted to elucidate metabolic pathways, it is 
prudent that, given their vulnerability for NAFLD, obese children and adolescents be 
monitored for aspartate aminotransferase and alanine aminotransferase elevations and 
other markers of liver function while on chronic acetaminophen at standard doses.  
 
Antibiotics historically represent the largest portion of published clinical research on 
drugs in obesity, with several reviews covering that topic in pediatrics87,88 and 
adults.89,90 In the PICU study, antibiotics were collectively the most prevalent 
therapeutic category, with vancomycin as the most commonly prescribed antibiotic 
followed by various parenteral cephalosporins. 
 
With the exception of antimicrobials, it is evident from this and other reviews of the 
literature that large gaps persist in our clinical knowledge about pharmacotherapy in 
pediatric obesity.91 In fact, a complete absence of pharmacokinetic information for 
obese children was noted by Rowe et al for 25 pediatric emergency care drugs.92 
 
Where adequate studies exist in adult populations but not pediatrics, it is not uncommon 
to consider utilizing knowledge obtained from adult obesity studies to inform dosing 
recommendations. A main benefit is averting drug exposure to a vulnerable population 
while optimizing use of existing data. Spanning nearly 4 decades, however, obesity drug 
studies represent a wide range of research designs and reporting criteria. In the case of 
small studies of low quality, interpretation of the findings might be limited to hypothesis 
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generation. Under certain circumstances, some drugs may deserve re-evaluation in 
well-designed controlled studies with application of modern technologies of sample and 
data analyses. 
  
Extrapolation from existing pharmacokinetic or pharmacodynamic data from adults to 
the pediatric population, in general, has limitations. It is currently not known whether 
common obesity in an adult population is physiologically similar to obesity in childrenf or 
adolescents.  
 
More knowledge is needed about the time course of adipocyte biology and 
pathophysiology and accompanying biochemical and metabolic changes to shed light 
on the validity of assumptions that may underlie extrapolation from other age groups 
with or without comorbidities. 
 
In adults there are different phenotypes of obesity, including the metabolically healthy 
and unhealthy phenotypes, and subtypes with differences in the cardiometabolic risk 
profile and intracellular pattern of fat distribution.93 Furthermore, in some patients the 
disease changes over time. The progression of some overweight children to obesity 
during adolescence and then possibly severe obesity in later adolescence or into 
adulthood calls into question the likelihood that youth-onset obesity is equivalent to 
adult-onset obesity.  
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A recent population pharmacokinetic modeling analysis of midazolam found that 
midazolam clearance in morbidly obese adults was not predictive of clearance in obese 
adolescents.94 
  
Clinical studies typically do not collect and/or report duration of obesity, but this may be 
a variable of importance, for example, to compare similarity at baseline of demography 
in the treatment groups. More research is needed on drug transporters, drug 
metabolizing enzymes and their polymorphisms in both youth and adults, to better 
predict how drug disposition and metabolism are affected along the spectrum of obesity, 
compounded over time with accumulation of obesity comorbidities. 
 
 
Concluding Remarks 
 
Obesity is a heterogenous chronic disease of energy balance and fuel partitioning. 
About one-third of youth in the United States are overweight or obese and the subgroup 
of severe obesity is showing a persistently upward trend. For treating obesity in children 
and adolescents, pharmacotherapy options added to lifestyle modification are limited to 
orlistat, metformin for comorbidities which on on-label, and possibly off-label use of 
adult-approved antiobesity agents in selected patients. Obese youth with comorbidities 
will require medications as part of their chronic disease management, yet very few 
drugs have been studied in children or adolescents with obesity. This is an area of high 
need for study, since adult obesity may differ from obesity in youth and findings from 
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pharmacokinetic investigations in obese adults may not predict pharmacokinetics in 
obese adolescents, as was shown with midazolam. Medication management should 
include judicious selection of drugs which will not hamper weight control. The highlights 
presented in this review of pediatric obesity pharmacotherapy should help prioritize 
areas of greatest need for further work. 
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Figure Legends 
 
Figure 1. The prevalence of obesity among youth in the United States shows an upward 
trend overall and by age subgroups of 2 to 5 years, 6 to 11 years, and 12 to 19 years.  
Data are from the Division of National Health and Nutrition Examination Surveys, 
reported through 2014. Pediatric definition of obesity is body mass index (BMI) ≥ 95th 
percentile using the sex-specific BMI-for-age 2000 Center for Disease Control (CDC) 
Growth Charts. 
 
Figure 2. Dotted line indicates overall mean percent (17.2%) of all US children and 
adolescents who are obese. Obesity prevalence data by ethnic/racial subgroups were 
obtained from the National Center for Health Statistics (NCHS), Division of National 
Health and Nutrition Examination Surveys, Health E-Stats, July 2016. Data from 
females exclude pregnant individuals. Pediatric definition of obesity is body mass index 
(BMI) ≥ 95th percentile using the sex-specific BMI-for-age 2000 Center for Disease 
Control (CDC) Growth Charts.  
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